Beam Therapeutics

(NASDAQ) BEAM

Current Price$31.21

Market Cap$3.39B

Since IPO (2020)+76%

5 Year-61%

1 Year+97%

1 Month+1%

Beam Therapeutics Financials at a Glance

Market Cap

$3.39B

Revenue (TTM)

$164.01M

Net Income (TTM)

-$65.04M

EPS (TTM)

-$0.69

P/E Ratio

-47.93

Dividend

$0.00

Beta (Volatility)

2.07 (High)

Dividend

$0.00

Beta (Volatility)

2.07 (High)

Price

$31.21

Volume

1,648,042.695

Open

$32.17

Price

$31.21

Volume

1,648,042.695

Open

$32.17

Previous Close

$31.14

Daily Range

$30.60 - $32.45

52-Week Range

$15.60 - $36.44

Dividend

$0.00

Beta (Volatility)

2.07 (High)

Price

$31.21

Volume

1,648,042.695

Open

$32.17

Previous Close

$31.14

Daily Range

$30.60 - $32.45

52-Week Range

$15.60 - $36.44

BEAM News

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Sara AppinoMay 18, 2026

DNA with a section separated from the main part.

Best CRISPR Gene Editing ETFs for 2026 and How to Invest

Keith SpeightsMay 11, 2026

A scientist looking through a microscope.

Best Biotech ETFs to Buy in 2026

Keith SpeightsApr 11, 2026

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

Robert IzquierdoApr 11, 2026

Page 1

BEAM: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Beam Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

511

CEO

John Evans, MBA

Website

www.beamtx.com

Headquarters

Cambridge, MA 02142, US

BEAM Financials

Key Financial Metrics (TTM)

Gross Margin

-32%

Operating Margin

-2%

Net Income Margin

-40%

Return on Equity

-6%

Return on Capital

-26%

Return on Assets

-4%

Earnings Yield

-2.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.39B

Shares Outstanding

102.88M

Volume

1.65M

Avg. Volume

2.10M

Financials (TTM)

Gross Profit

$117.45M

Operating Income

-$383.69M

EBITDA

-$29.92M

Operating Cash Flow

-$345.10M

Capital Expenditure

-$14.95M

Free Cash Flow

-$360.05M

Cash & ST Invst.

$1.25B

Total Debt

$293.88M

Beam Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$31.74M

+324.9%

Gross Profit

$31.74M

+134.7%

Gross Margin

100.00%

N/A

Market Cap

$3.39B

N/A

Market Cap/Employee

$8.62M

N/A

Employees

393

N/A

Net Income

-$94.32M

+13.7%

EBITDA

-$101.61M

+10.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$960.83M

-9.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$236.04M

+62.9%

Short Term Debt

$14.78M

+11.9%

Return on Assets

-4.39%

N/A

Return on Invested Capital

-26.43%

N/A

Free Cash Flow

-$130.75M

-22.2%

Operating Cash Flow

-$128.51M

-23.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

DNLIDenali Therapeutics Inc.

DNLIDenali Therapeutics Inc.$20.41-2.99%

RCUSArcus Biosciences, Inc.

RCUSArcus Biosciences, Inc.$25.67+1.30%

IDYAIDEAYA Biosciences, Inc.

IDYAIDEAYA Biosciences, Inc.$28.94-1.80%

ETNB89bio, Inc.

ETNB89bio, Inc.$14.84+0.00%

MLYSMineralys Therapeutics, Inc.

MLYSMineralys Therapeutics, Inc.$31.11-1.24%

RXRXRecursion Pharmaceuticals, Inc.

RXRXRecursion Pharmaceuticals, Inc.$3.79+5.57%

AGIOAgios Pharmaceuticals, Inc.

AGIOAgios Pharmaceuticals, Inc.$28.00-4.76%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCEVirgin Galactic

SPCEVirgin Galactic$7.52+0.22%

INTCIntel

INTCIntel$109.33-0.05%

HKITHitek Global

HKITHitek Global$6.58+3.51%

ONDSOndas

ONDSOndas$13.46+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.47-0.09%

RGTIRigetti Computing

RGTIRigetti Computing$25.63+0.00%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.34-0.02%

Questions About BEAM

What is the current price of Beam Therapeutics?

Beam Therapeutics is trading at $31.14 per share.

What is the 52-week range for Beam Therapeutics?

Over the past 52 weeks, Beam Therapeutics has traded between $15.60 and $36.44.

How much debt does Beam Therapeutics have?

As of the most recent reporting period, Beam Therapeutics reported total debt of $250.82M.

How much cash does Beam Therapeutics have on hand?

Beam Therapeutics reported $288.29M in cash and cash equivalents in its most recent financial results.

What is Beam Therapeutics’s dividend yield?

Beam Therapeutics does not currently have a dividend yield.

Beam Therapeutics

Beam Therapeutics Financials at a Glance

BEAM News

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Best CRISPR Gene Editing ETFs for 2026 and How to Invest

Best Biotech ETFs to Buy in 2026

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

Best Gene Editing Stocks for 2026 and How to Invest

Best CRISPR Companies to Buy in 2026 and How to Invest in Them

Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933

Why Beam Therapeutics Stock Tanked on Tuesday

BEAM: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Beam Therapeutics

BEAM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Beam Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BEAM

What is the current price of Beam Therapeutics?

What is the 52-week range for Beam Therapeutics?

How much debt does Beam Therapeutics have?

How much cash does Beam Therapeutics have on hand?

What is Beam Therapeutics’s dividend yield?

Premium Investing Services